Sinopharm Group Co. Ltd.
HKEX:1099.HK
19.88 (HKD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 596,569.565 | 552,147.55 | 521,051.235 | 456,414.611 | 425,272.726 | 344,525.821 | 277,028.977 | 258,117.225 | 228,672.929 | 200,131.261 | 166,866.146 | 135,786.836 | 102,224.807 | 69,233.669 | 47,045.853 | 38,187.433 | 31,110.214 | 23,736.642 |
| Cost of Revenue
| 548,057.887 | 504,713.49 | 477,000.627 | 416,091.3 | 387,741.423 | 313,297.729 | 254,640.464 | 237,717.016 | 209,952.616 | 183,803.043 | 153,487.63 | 124,844.238 | 93,870.11 | 63,397.799 | 43,261.285 | 35,152.478 | 28,559.991 | 21,747.1 |
| Gross Profit
| 48,511.678 | 47,434.06 | 44,050.608 | 40,323.311 | 37,531.303 | 31,228.092 | 22,388.513 | 20,400.209 | 18,720.313 | 16,328.218 | 13,378.516 | 10,942.598 | 8,354.697 | 5,835.87 | 3,784.568 | 3,034.955 | 2,550.223 | 1,989.542 |
| Gross Profit Ratio
| 0.081 | 0.086 | 0.085 | 0.088 | 0.088 | 0.091 | 0.081 | 0.079 | 0.082 | 0.082 | 0.08 | 0.081 | 0.082 | 0.084 | 0.08 | 0.079 | 0.082 | 0.084 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 8,678.071 | 8,183.559 | 7,760.993 | 7,049.812 | 6,912.227 | 5,517.883 | 4,187.139 | 4,110.38 | 3,674.015 | 3,510.803 | 3,052.707 | 2,568.435 | 1,964.629 | 1,544.407 | 1,036.849 | 966.727 | 839.587 | 747.602 |
| Selling & Marketing Expenses
| 17,471.692 | 16,719.561 | 15,437.533 | 14,141.741 | 12,556.928 | 10,369.831 | 7,383.263 | 6,618.858 | 6,024.832 | 5,122.849 | 4,473.773 | 3,729.715 | 2,922.793 | 1,960.018 | 1,250.304 | 966.013 | 945.284 | 778.961 |
| SG&A
| 26,149.763 | 24,903.12 | 23,198.526 | 21,191.553 | 19,469.155 | 15,887.714 | 11,570.402 | 10,729.238 | 9,754.721 | 8,681.04 | 7,585.663 | 6,298.15 | 4,887.422 | 3,504.425 | 2,287.153 | 1,932.74 | 1,784.871 | 1,526.563 |
| Other Expenses
| -41.803 | -676.163 | -589.193 | -652.002 | -441.164 | -413.764 | -399.814 | 4.923 | 1.501 | 22.795 | -7.638 | 9.667 | -168.941 | 171.381 | 171.195 | 92.749 | 124.137 | -45.633 |
| Operating Expenses
| 26,234.719 | 24,226.957 | 22,609.333 | 20,539.551 | 19,027.991 | 15,473.95 | 11,170.588 | 10,456.953 | 9,436.49 | 8,401.029 | 7,237.775 | 6,079.251 | 4,718.481 | 3,427.055 | 2,234.289 | 1,862.817 | 1,760.877 | 1,509.291 |
| Operating Income
| 20,209.195 | 20,604.466 | 19,711.976 | 17,759.975 | 16,136.744 | 15,396.806 | 11,905.966 | 10,213.72 | 9,209.322 | 7,851.199 | 6,081.794 | 4,863.347 | 3,636.216 | 2,408.815 | 1,550.279 | 1,172.138 | 789.346 | 480.251 |
| Operating Income Ratio
| 0.034 | 0.037 | 0.038 | 0.039 | 0.038 | 0.045 | 0.043 | 0.04 | 0.04 | 0.039 | 0.036 | 0.036 | 0.036 | 0.035 | 0.033 | 0.031 | 0.025 | 0.02 |
| Total Other Income Expenses Net
| -2,806.35 | -2,040.647 | -2,708.814 | -2,161.879 | -2,376.934 | -3,188.866 | -1,732.962 | -1,288.898 | -1,740.149 | -1,916.596 | -1,461.289 | -849.094 | -508.616 | -10.863 | 22.093 | -94.749 | 31.063 | -116.284 |
| Income Before Tax
| 19,512.137 | 18,563.819 | 17,003.162 | 15,598.096 | 13,759.81 | 12,207.94 | 10,173.004 | 8,924.822 | 7,469.173 | 5,934.603 | 4,620.505 | 4,014.253 | 3,127.6 | 2,397.952 | 1,572.372 | 1,077.389 | 820.409 | 363.967 |
| Income Before Tax Ratio
| 0.033 | 0.034 | 0.033 | 0.034 | 0.032 | 0.035 | 0.037 | 0.035 | 0.033 | 0.03 | 0.028 | 0.03 | 0.031 | 0.035 | 0.033 | 0.028 | 0.026 | 0.015 |
| Income Tax Expense
| 4,502.309 | 4,218.377 | 3,938.389 | 3,500.805 | 3,139.738 | 2,803.456 | 2,304.828 | 2,033.227 | 1,728.264 | 1,383.03 | 1,040.793 | 934.117 | 725.05 | 567.595 | 386.234 | 259.286 | 284.46 | 181.519 |
| Net Income
| 9,053.76 | 14,345.442 | 13,064.773 | 12,097.291 | 10,620.072 | 9,404.484 | 7,868.176 | 4,647.344 | 3,760.649 | 2,874.823 | 2,250.002 | 1,973.823 | 1,560.606 | 1,208.751 | 845.819 | 818.103 | 535.949 | 182.448 |
| Net Income Ratio
| 0.015 | 0.026 | 0.025 | 0.027 | 0.025 | 0.027 | 0.028 | 0.018 | 0.016 | 0.014 | 0.013 | 0.015 | 0.015 | 0.017 | 0.018 | 0.021 | 0.017 | 0.008 |
| EPS
| 2.9 | 4.6 | 4.2 | 3.89 | 3.58 | 3.17 | 2.65 | 1.68 | 1.36 | 1.11 | 0.89 | 0.82 | 0.66 | 0.53 | 0.53 | 0.36 | 0.23 | 0.06 |
| EPS Diluted
| 2.9 | 4.6 | 4.2 | 3.89 | 3.57 | 3.16 | 2.65 | 1.68 | 1.36 | 1.11 | 0.89 | 0.82 | 0.66 | 0.53 | 0.53 | 0.36 | 0.23 | 0.06 |
| EBITDA
| 28,329.036 | 28,809.231 | 26,865.051 | 24,905.6 | 22,799.525 | 18,067.38 | 13,431.593 | 11,638.957 | 10,125.033 | 8,610.667 | 6,701.861 | 5,630.27 | 4,521.243 | 3,047.107 | 2,013.694 | 1,516.104 | 1,106.207 | 592.222 |
| EBITDA Ratio
| 0.047 | 0.052 | 0.052 | 0.055 | 0.054 | 0.052 | 0.048 | 0.045 | 0.044 | 0.043 | 0.04 | 0.041 | 0.044 | 0.044 | 0.043 | 0.04 | 0.036 | 0.025 |